MTOR inhibitors are a class of drugs that target the mammalian target of rapamycin (mTOR) protein, which plays a crucial role in regulating cell growth, proliferation, and survival. These inhibitors are used in the treatment of certain cancers, as well as other diseases such as tuberous sclerosis complex and lymphangioleiomyomatosis. By blocking the activity of mTOR, these inhibitors can help slow down the growth and spread of cancer cells, potentially leading to improved outcomes for patients. Current research in this area focuses on developing more effective mTOR inhibitors, improving their specificity and reducing side effects, as well as exploring their potential for combination therapies with other cancer treatments.